地塞米松
医学
皮质类固醇
水肿
脑水肿
磁共振成像
内科学
糖皮质激素
生理盐水
内分泌学
病理
核医学
放射科
作者
Juri Gelovani Tjuvajev,Hisao Uehara,Revathi Desai,Bradley J. Beattie,Cornelia Matei,Yan Zhou,Mary Jeanne Kreek,Jason A. Koutcher,Ronald G. Blasberg
出处
期刊:PubMed
日期:1996-03-15
卷期号:56 (6): 1352-60
被引量:12
摘要
We report the first series of studies comparing the anti-edematous effects of human corticotropin-releasing factor (hCRF) and dexamethasone in an experimental model of vasogenic peritumoral brain edema. Both hCRF and dexamethasone effectively decreased blood-brain barrier (BBB) permeability of intracerebral RG2 gliomas in rats as observed by contrast-enhanced T(1)-weighted magnetic resonance imaging. A decrease in the water content of tumor and peritumoral brain tissue was observed with proton-density magnetic resonance imaging and confirmed by direct wet/dry tissue measurements. The calculated ED(50) for hCRF was 59 micrograms/kg s.c. twice a day, and that for dexamethasone was 0.61 mg/kg i.m. twice a day; the hCRF:dexamethasone dose-potency ratio was 120:1 on a molar basis. The anti-edematous action of hCRF is not mediated by the release of adrenal corticosteroids. A direct action of hCRF on the tumor microvasculature results in restoration of BBB integrity and up-regulation of BBB-specific protein expression. The average survival time with chronic treatment was prolonged significantly in the hCRF-treated group (35 days) compared with the dexamethasone-treated group (28 days; P < 0.05) and the saline-treated control group (22 days; P < 0.0001). hCRF, as an alternative to corticosteroid therapy, may provide substantial benefits with respect to reducing the major side effects encountered with long-term, high-dose corticosteroid treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI